poisar

Stocks · News reference

Charles River Laboratories Exec Says Continue To Expect Lower Volumes For Research Models In North America, Spending From Academic And Government Clients Has Been Constrained By Flat NIH Budgets And Slower Grant Processing; Q3 Adj EPS Expected At $2.90 - $3; Well Positioned To Support Our Acquisition Strategy, We'd Love To Be Able To Add A Couple Additional Companies To Our Portfolio

Aug 5, 2026, 1:46 PMBenzinga Newsdesk

-Conference Call

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CRL
Source
benzinga
Observed
Aug 5, 2026, 1:46 PM
Checked
Aug 5, 2026, 1:46 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 10:52 AMResearchandmarkets.Com

    Animal Testing and Non-Animal Alternative Testing Market Outlook 2025-2035 - Featuring Profiles of Charles River Laboratories, Labcorp, and Eurofins Scientific

    The global animal testing and non-animal alternative testing market reached $15.19 billion in 2025 and is projected to grow to $23.01 billion by 2035 at a CAGR of 4-4.5%. While animal testing dominated with 80.1% market share in 2025, non-animal alternative testing is expected to grow faster at 6.3% CAGR through 2030, driven by advances in organ-on-chip, organoids, AI biosimulation, and genomics. The pharmaceutical industry led end-user applications with 50.1% market share, while North America was the largest regional market at 38.6% of global revenue.

    Read original at globenewswire-inc
    CRLLHERRFY
  2. Aug 26, 2026, 11:58 AMResearchandmarkets.Com

    Large Molecule Bioanalytical Testing Services Global Market Report 2026-2035 | Identify High-Growth Opportunities and Develop Informed Commercial Strategies

    The global large molecule bioanalytical testing services market is projected to grow from USD 3.11 billion in 2026 to USD 5.88 billion by 2035, with a CAGR of 7.3%. Growth is driven by increasing biologics pipelines, demand for personalized therapies, and outsourcing to CROs and CDMOs. Pharmacokinetics testing dominates at 45% of market revenue, while bioequivalence testing is expected to grow fastest. North America leads with 50% of global revenue, while Asia-Pacific is the fastest-growing region at 8.6% CAGR.

    Read original at globenewswire-inc
    CRLERRFYWUXAYSGSOY